Heart-Monitoring Device Scores Tech Award

Posted: Updated:
The Arrhythmotech team won Innovation of the Year at TechPoint's Mira Awards. The Arrhythmotech team won Innovation of the Year at TechPoint's Mira Awards.

A technology that could alert doctors that a patient is at risk of sudden cardiac death took a top prize at the recent 18th Annual Mira Awards, presented by Indiana’s tech initiative TechPoint. Arrhythmotech’s device detects which cardiology patients are in such life-threatening situations by simply attaching sensors to the skin. Awarded Innovation of the Year in the product category at the Mira Awards, Arrhythmotech says detecting cardiac emergencies is likely just the beginning.

Based in Indianapolis at the Indiana Center for Biomedical Innovation, Arrhythmotech says its neuECG device records and processes sympathetic nerve activity and electrocardiogram signals. A conventional ECG (or EKG) focuses only on the latter measurement, but Arrhythmotech’s device adds sympathetic nerve activity to the picture.

Sympathetic nerve activity operates fundamental involuntary processes in the body, including a person’s breathing, heartbeat and digestive system. The startup will initially focus on cardiology applications; the device aims to detect patients with arrhythmia—an irregular heartbeat—and also flag patients at risk of sudden cardiac death.

Arrhythmotech Chief Executive Officer Joe Trebley says the current standard method for measuring sympathetic nerve activity is an invasive procedure that attaches electrodes directly to a nerve; Arrhythmotech’s device can capture the same information on a patient’s skin.

The technology is based on research conducted by Indiana University School of Medicine (IUSM) Medtronic Zipes Chair in Cardiology Dr. Peng-Sheng Chen. Because the technology directly measures part of the body’s stress response, the startup believes its applications reach far beyond cardiology.

Arrhythmotech is working to miniaturize the device into a wearable technology, much like a Fitbit-type product. Trebley says potential applications include predicting seizures for patients with epilepsy, monitoring performance for athletes and helping people with sleep apnea. 

“With seizures, even if you’re only right half the time, it’s good to give the patient a signal that, if you’re driving a car, you may need to pull over,” says Trebley. “Once we get this into something that’s wearable—miniaturized—I think the power is going to be demonstrated, and that’s going to be a real takeoff point for us. You can imagine patches that can tell you your stress level—something like that will be very exciting to develop over the next couple years.”

Arrhythmotech worked with Rose-Hulman Ventures to develop a beta version of the neuECG, which is being tested at IUSM and other institutions throughout the country. Trebley says the device currently consists of ECG cuffs, three leads that attach to the chest or wrist and a box slightly larger than an iPhone, “but there’s nothing insurmountable about miniaturizing it all into something that’s wearable.”

Arrhythmotech has earned two small business grants from the National Institutes of Health totaling more than $1.5 million. While the device is gaining traction in the medical space, Trebley says the Mira award validates neuECG in the tech space.

“We’re just a bunch of physicians and biomedical engineers not terribly connected within the tech community,” says Trebley. “I think a lot of what we’ll be able to unpack has to do with not just the hardware—because it’s not terribly complicated hardware—but in the software and data analytics. We’re bringing some important data to play here, and it could be really impactful. Hopefully, we’ll get some attention from [experts] in data analytics and software development and plug into those business models.”

Arrhythmotech is focusing now on “driving acceptance of [neuECG’s] technique” and conducting studies to demonstrate its predictive power.

“We’re getting interest from groups in the wearable space, or in epilepsy, or in pain, who are beginning to say, ‘This could be really interesting to plug into what we’re doing,’” says Trebley. “We’re focused on the cardiology space currently, but I think what’s really fun about this technology is, its killer application is likely to be something we haven’t even thought of yet.”

Trebley says certain applications for the neuECG will require FDA approval.
Trebley says several organizations within Indiana have played a critical role in Arrhythmotech’s development.
  • Perspectives

    • How Telling Your Customers 'No' Can Improve Loyalty

      Business usually try to convert customers into loyalists by giving them what they want. That statement seems obvious... until it's not. Take Milktooth in Indianapolis, for example. The restaurant has become a star of the food scene by telling customers "no." This flies in the face of what most businesses consider to be standard operating procedure. But for Milktooth, saying no is simply good business.

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • ‘Invisible’ Digital Twins Taking Flight at GE Aviation

      As aircraft engines roll off the production line at GE Aviation in Lafayette, workers there are also producing “ghost” engines of sorts, called digital twins. 

    • Construction to Begin on $15M Noblesville Fieldhouse

      City and development officials will break ground Friday on a $15 million sports complex in Noblesville. Finch Creek Park Fieldhouse will include five courts with hard surfaces, two turf-surfaced fields and 11 batting and pitching cages. The project, which was first unveiled a year ago, is a public-private partnership between Klipsch-Card Athletic Facilities LLC and the city. The company is also owner/operator of the fieldhouse at Grand Park in Westfield.

    • Historic Indy Building to Become Hotel

      A nearly 110-year-old building in downtown Indianapolis will soon have new life. Indianapolis-based real estate development firm Loftus Robinson is partnering with Kimpton Hotels & Restaurants in California to transform the former Odd Fellows building into a 130-room hotel with a signature restaurant. Financial terms of the project are not being disclosed, however the developer says the hotel is scheduled to open in early 2020 and create about 150 hotel and restaurant jobs.

    • Lilly Cancer Treatment Falls Short in Study

      Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has announced it will not seek regulatory approval on another use for one of the key treatments in its cancer portfolio. In a late-stage study, CYRAMZA met its main goal of progression free-survival in patients with HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma, but did not improve a secondary endpoint: overall survival rate.

    • How Telling Your Customers 'No' Can Improve Loyalty

      Business usually try to convert customers into loyalists by giving them what they want. That statement seems obvious... until it's not. Take Milktooth in Indianapolis, for example. The restaurant has become a star of the food scene by telling customers "no." This flies in the face of what most businesses consider to be standard operating procedure. But for Milktooth, saying no is simply good business.